Sutro Biopharma, Inc.
- Last sale
- Nov 12, 2026 · -6.54%
- Market cap
- $158.96M
- 16.6M shares
- Filings
- 628
Q3 2026+65.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q1 2020derivedN/M FY18 yoy
Q3 2026N/M FY25 yoy
Q3 2026−69.5% FY25 yoy
- $158.96M
- —
- 3.5×
- —
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $102,484,000 | reported | |
| FY 2024 | 2024-12-31 | $62,043,000 | reported | |
| FY 2023 | 2023-12-31 | $153,731,000 | reported | |
| FY 2022 | 2022-12-31 | $67,772,000 | reported | |
| FY 2021 | 2021-12-31 | $61,880,000 | reported | |
| FY 2020 | 2020-12-31 | $42,722,000 | reported | |
| FY 2019 | 2019-12-31 | $42,736,000 | reported | |
| FY 2018 | 2018-12-31 | $38,419,000 | reported | |
| FY 2017 | 2017-12-31 | $51,741,000 | reported | |
| FY 2016 | 2016-12-31 | $59,731,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2021 | — | $7.00K | $7.00K | — | 46.38M sh | +1.1% | — |
Biological products, except diagnostic substances
Sutro Biopharma, Inc. is the 31st largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
GLUEMonte Rosa Therapeutics, Inc.$123.7M63.5%31.2%$793.0MATRAAtara Biotherapeutics, Inc.$120.8M6.3%27.1%$80.4MAGENAgenus Inc$114.2M10.4%2.7%$323.1MIBRXImmunityBio, Inc.$113.3M668.3%310.2%$6.5BIPSCCentury Therapeutics, Inc.$109.2M1,556.8%8.8%$294.2M
STROSutro Biopharma, Inc. (this company)$102.5M65.2%186.5%$159.0M
FDMT4D Molecular Therapeutics, Inc.$85.2M230,194.6%164.4%$682.1MMGTXMeiraGTx Holdings plc$81.4M144.6%140.3%$858.1MAUTLAutolus Therapeutics plc$75.4M644.9%381.4%$318.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR